Form 8-K Senseonics Holdings, For: Mar 12

Thu, 12 Mar 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260312/26153012.html

Form 8-K Senseonics Holdings, For: Mar 12

Thu, 12 Mar 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260312/26153012.html

Stifel Reiterates Hold Rating on Senseonics Holdings (SENS)

Tue, 03 Mar 2026 09:33:16 -0400

Stifel analyst Jonathan Block reiterated a Hold rating and $9.00 price target on Senseonics Holdings (NYSE: SENS).

The analyst commented, "The 4Q25 revenue results were in-line with the January preannouncement. Gross margin was better than expected, but this was offset by higher-than-expected operating expenses, which led to an EBIT loss of ($21MM), a bit worse than our ($19MME) and the level of cash burn matters. For 2026, the revenue guidance ($58-62MM) was previously conveyed, along with GM (~50%) but the opex guidance (and as a result the cash burn) was ~$25MM above our expectations, leading to the company likely accessing its

Form 10-K Senseonics Holdings, For: Dec 31

Mon, 02 Mar 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260302/26092996.html

Form 10-K Senseonics Holdings, For: Dec 31

Mon, 02 Mar 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260302/26092996.html

Form 8-K Senseonics Holdings, For: Mar 02

Mon, 02 Mar 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260302/26092868.html

Form 8-K Senseonics Holdings, For: Mar 02

Mon, 02 Mar 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260302/26092868.html

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

Mon, 02 Mar 2026 16:01:00 -0400

Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year

Received CE Mark approval for commercialization of Eversense 365 in Europe

Launched first Eversense 365 AID system integration, with twiist in the US

GERMANTOWN, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced fourth quarter 2025 financial results and provided a business update.

Recent Highlights & Accomplishments

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

Mon, 02 Mar 2026 16:01:00 -0400

Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year

Received CE Mark approval for commercialization of Eversense 365 in Europe

Launched first Eversense 365 AID system integration, with twiist in the US

GERMANTOWN, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced fourth quarter 2025 financial results and provided a business update.

Recent Highlights & Accomplishments
- Sequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365
  
  Thu, 19 Feb 2026 08:00:00 -0400
  
  The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes
  MANCHESTER, N.H. and GERMANTOWN, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing transformative drug delivery technologies, and Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on long-term, implantable Continuous Glucose Monitoring (CGM) systems for people with diabetes, today announced full availability of the twiist™ Automated Insulin Delivery (AID) System integrated with the Eversense® 365 CGM system across the U.S.
  
  Powered by
  
  Sequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365
  
  Thu, 19 Feb 2026 08:00:00 -0400
  
  The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes
  MANCHESTER, N.H. and GERMANTOWN, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing transformative drug delivery technologies, and Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on long-term, implantable Continuous Glucose Monitoring (CGM) systems for people with diabetes, today announced full availability of the twiist™ Automated Insulin Delivery (AID) System integrated with the Eversense® 365 CGM system across the U.S.
  
  Powered by
  
  Sequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365
  
  Thu, 19 Feb 2026 08:00:00 -0400
  
  The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes
  MANCHESTER, N.H. and GERMANTOWN, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing transformative drug delivery technologies, and Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on long-term, implantable Continuous Glucose Monitoring (CGM) systems for people with diabetes, today announced full availability of the twiist™ Automated Insulin Delivery (AID) System integrated with the Eversense® 365 CGM system across the U.S.
  
  Powered by
  
  Sequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365
  
  Thu, 19 Feb 2026 08:00:00 -0400
  
  The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes
  MANCHESTER, N.H. and GERMANTOWN, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing transformative drug delivery technologies, and Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on long-term, implantable Continuous Glucose Monitoring (CGM) systems for people with diabetes, today announced full availability of the twiist™ Automated Insulin Delivery (AID) System integrated with the Eversense® 365 CGM system across the U.S.
  
  Powered by
  
  Senseonics gets European approval for year-long glucose monitor
  
  Thu, 29 Jan 2026 16:01:35 -0400
  
  Senseonics Holdings Inc. (NASDAQ: SENS) received CE Mark approval for its Eversense 365 continuous glucose monitoring system in Europe, the company announced. The approval allows commercialization of the device across the European Union.
  The Eversense 365 is an implantable glucose monitor with a 365-day sensor duration. The U.S. Food and Drug Administration approved the device in September 2024, and it launched in the United States in October 2024.
  Senseonics submitted the CE Mark application in compliance with EU Medical Device Regulation. The company plans to launch Eversense 365 in Germany, Italy, Spain and Sweden in the coming months.
  "European approval for Eversense 365
  
  Senseonics Receives European Approval for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor
  
  Thu, 29 Jan 2026 16:01:00 -0400
  
  GERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced CE Mark approval for the Eversense^® 365 CGM system.
  
  Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of the same year.
  
  The Eversense 365 CE Mark submission was prepared in compliance with
  
  Senseonics Receives European Approval for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor
  
  Thu, 29 Jan 2026 16:01:00 -0400
  
  GERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced CE Mark approval for the Eversense^® 365 CGM system.
  
  Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of the same year.
  
  The Eversense 365 CE Mark submission was prepared in compliance with
  
  Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
  
  Wed, 28 Jan 2026 16:05:00 -0400
  
  GERMANTOWN, Md., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, Utah.
  
  To request a meeting with Senseonics, investors should contact their BTIG representatives.
  
  About Senseonics
  
  Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of
  
  Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
  
  Wed, 28 Jan 2026 16:05:00 -0400
  
  GERMANTOWN, Md., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, Utah.
  
  To request a meeting with Senseonics, investors should contact their BTIG representatives.
  
  About Senseonics
  
  Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of
  
  Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
  
  Wed, 28 Jan 2026 16:05:00 -0400
  
  GERMANTOWN, Md., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, Utah.
  
  To request a meeting with Senseonics, investors should contact their BTIG representatives.
  
  About Senseonics
  
  Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring
  
  Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
  
  Wed, 28 Jan 2026 16:05:00 -0400
  
  GERMANTOWN, Md., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, Utah.
  
  To request a meeting with Senseonics, investors should contact their BTIG representatives.
  
  About Senseonics
  
  Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring
  
  Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
  
  Wed, 28 Jan 2026 16:05:00 -0400
  
  GERMANTOWN, Md., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, Utah.
  
  To request a meeting with Senseonics, investors should contact their BTIG representatives.
  
  About Senseonics
  
  Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring
  
  Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
  
  Wed, 28 Jan 2026 16:05:00 -0400
  
  GERMANTOWN, Md., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, Utah.
  
  To request a meeting with Senseonics, investors should contact their BTIG representatives.
  
  About Senseonics
  
  Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring
  
  Form 8-K Senseonics Holdings, For: Jan 12
  
  Mon, 12 Jan 2026 08:26:00 -0400
  si-local-file:///var/storage/secattach/20260112/25834834.html
  
  Form 8-K Senseonics Holdings, For: Jan 12
  
  Mon, 12 Jan 2026 08:26:00 -0400
  si-local-file:///var/storage/secattach/20260112/25834834.html
  
  Senseonics reports Q4 revenue of $14.2 million, up 71% year-over-year
  
  Mon, 12 Jan 2026 08:00:57 -0400
  
  Senseonics Holdings Inc. (NASDAQ: SENS) reported preliminary unaudited revenue of approximately $14.2 million for the fourth quarter of 2025, representing a 71% increase compared to the same period in 2024. The medical technology company also reported full-year 2025 revenue of approximately $35.2 million, up 57% year-over-year.
  The company achieved 103% new patient growth in the U.S. during the fourth quarter compared to the same period in 2024, driven by direct-to-consumer marketing efforts. Senseonics develops implantable continuous glucose monitoring systems for people with diabetes.
  For 2026, Senseonics provided revenue guidance of $58-$62 million, representing a projected increase of 65% to 76% over 2025

StreetInsider.com News Articles

Form 8-K Senseonics Holdings, For: Mar 12

Form 8-K Senseonics Holdings, For: Mar 12

Stifel Reiterates Hold Rating on Senseonics Holdings (SENS)

Form 10-K Senseonics Holdings, For: Dec 31

Form 10-K Senseonics Holdings, For: Dec 31

Form 8-K Senseonics Holdings, For: Mar 02

Form 8-K Senseonics Holdings, For: Mar 02

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

Sequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365

Sequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365

Sequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365

Sequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365

Senseonics gets European approval for year-long glucose monitor

Senseonics Receives European Approval for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor

Senseonics Receives European Approval for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor

Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Form 8-K Senseonics Holdings, For: Jan 12

Form 8-K Senseonics Holdings, For: Jan 12

Senseonics reports Q4 revenue of $14.2 million, up 71% year-over-year